Inhibin A and B, Tumor Marker

Abbrev Code:MAYO INHAB   
Order Code:LAB1059Order Name:Inhibin A and B, Tumor Marker
Synonyms:LHE LAB1124
Methodology:Inhibin A assay is a sequential 2-step immunoenzymatic sandwich assay.
Inhibin B is an ultra-sensitive Inhibin B ELISA 3-step sandwich assay.
CPT Codes: 83520 x1, 86336 x1, 83520 x1, 86336 x1
Turnaround Time:Specimens are sent to the reference laboratory Mon-Sat. Inhibin A is performed Mon-Sat; Inhibin B is performed Mon, Wed, Fri. Results are reported within 1-6 days.

This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. This test has not been cleared or approved by the U.S. Food and Drug Administration.

Collection Instructions

Optimal Volume:1.5 mL
Minimum\Peds Volume:1.0 mL
Container:Red or gold (gel)
Alternate Containers: Red (no gel)
Causes for Rejection:Grossly hemolyzed sample.

Processing and Shipping

Specimen Processing:Centrifuge and aliquot 0.6 mL, 0.4 mL minimum. Store in refrigerator.
Shipping Instructions:Ship at refrigerated temperature.
Stability:14 days refrigerated (preferred); 90 days frozen.
Test Performed at or Referral Lab Lab Sendouts  (Mayo Medical Laboratories)
Referral Lab number:INHAB


Reference Range:Inhibin A, Tumor Marker:
Female   Male  
Age pg/mL Age pg/mL
<11 y <4.7 All <2.0
11-17 y <97.5    
Premenopausal <97.5    
Postmenopausal <2.1    

Inhibin B, Tumor Marker:
Female   Male  
Age pg/mL Age pg/mL
≤ 2 y <183 <15 d 68-373
13-41 y regular cycle
(Follicular Phase)
<224 15-180 d 42-516
42-51 y regular cycle
(Follicular Phase)
<108 6 mo - 7 y 24-300
13-51 y regular cycle
(Luteal Phase)
<80 8-30 y 47-383
>51 y
<12 31-72 y <358
    >72 y Not

INTERPRETATION Inhibin A levels are elevated in approximately 70% of patients with granulosa cell tumors and in approximately 20% of patients with epithelial ovarian tumors. Inhibin B levels are elevated in approximately 89-100% of patients with granulosa cell tumors and in approximately 55-60% of patients with epithelial ovarian tumors. A normal Inhibin A or B level does not rule out a mucinous or granulosa ovarian cell tumor.

For monitoring patients with known ovarian cancer, Inhibin A and B levels decrease shortly after surgery. Elevations of Inhibin A or B after treatment are suggestive of residual, recurrent or progressive disease. In patients with recurrent disease, Inhibin A or B elevation seems to be present earlier than clinical symptoms. Patients in remission show normal levels of Inhibin A and B. For infertility evaluation, an Inhibin B level in the postmenopausal range is suggestive of a diminished or depleted ovarian reserve.


Inhibin values fluctuate during the menstrual cycle. Inhibin levels in premenopausal women should be interpreted with caution. Do not interpret serum inhibin levels as absolute evidence of the presence or the absence of malignant disease. Use results in conjunction with information from the clincal evaluation of the patient and other diagnostic procedures. Tumor markers are not specific for malignancy and values may vary by testing methodology. The same method should be used to serially monitor patients. Some patients who have been exposed to animal antigens, either in the enviroment or as part of treatment or imaging procedures, may have circulating anti-animal antibodies present. These antibodies may interfere with the assay reagents to produce unreliable results.  
  • Aid in the diagnosis of granulosa cell tumors and mucinous epithelial ovarian tumors.
  • Monitor patients with granulosa cell tumors and epithelial mucinous type tumors of the ovary known to secrete Inhibin A or overexpress Inhibin B.

Click HERE to Report test errors or omissions.
*If no email program is associated with this computer, please contact: for TestID: 6935"